Antiviral Drugs Market

Antiviral Drugs Market by Mechanism of Action, Target Indication, Type of Drug Target, Type of Therapy and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    744

  • Pages
    245

  • View Count
    11436

Antiviral Drugs Market Overview

The antiviral drugs market is estimated to be worth $57 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 6.3% during the forecast period.

Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030. Over the past few years, a number of flu medicine and different types of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life-threatening infectious diseases in humans. Further, several antiviral drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics.

The antiviral medications development is fraught with several challenges, including emergence of drug resistance in viruses (as viruses can frequently mutate their genome) and concerns related to drug safety and efficacy. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the R&D efforts for the development of effective antiviral therapeutics against the known viral targets. The COVID-19 pandemic also exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases; this has created opportunities for the development of novel antiviral medications that can be effective against multiple viruses. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral medications, worldwide. These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates. Moreover, in order to fund product development initiatives in antiviral drugs market, various private and public sector investors have invested around USD 5.5 billion across multiple instances. Driven by the increasing demand for safe and effective antivirals, ongoing pace of innovation in antiviral drugs market, recent partnership activity and sufficient financial support from investors, the antiviral drugs market is anticipated to witness substantial market growth during the forecast period.

This image provides list of Approved Antiviral Drugs. Close to 80 antiviral drugs have been approved, till date, for the treatment of an array of infectious diseases; nearly 75% of these drugs are administered via oral route This image provides a detailed assessment of the current market landscape of clinical-stage antiviral drugs. Around 90% of the approved antiviral drugs are available in tablet and liquid formulations; most of the drugs are small molecules, designed for use against various infectious diseases at different dosing regimens This image provides list of Clinical-Stage Antiviral Drugs. Currently, around 430 drug candidates are being investigated in various phases of clinical trials for the treatment of multiple infectious diseases; majority of the drug molecules are being evaluated as monotherapies

Key Companies in Antiviral Drugs Market

Examples of key companies engaged in antiviral drugs market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Novartis, Pfizer, Roche and ViiV Healthcare. This market report includes an easily searchable excel database of all the companies developing antiviral drugs, worldwide.

Recent Developments in Antiviral Drugs Market

Several recent developments have taken place in the field of antiviral drugs market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In July 2023, Griffith University entered into a commercial partnership with Gene Company for USD 135 million to develop a RNA-based COVID anti-viral drugs. 
  • In May 2023, Pfizer announced the FDA approval of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) used for the treatment of adults having mild-to-moderate COVID-19. 
  • In March 2023, Emory entered into a collaboration with Pfizer in order to advance the discovery of antiviral agents for COVID-19. 

Scope of the Report

The ‘Antiviral Drugs Market, 2022-2035: Distribution by Mechanism of Action (Fusion Inhibitors, DNA Polymerases, Protease Inhibitors, Reverse Transcriptase Inhibitors and Others), Target Indication (Human Immunodeficiency virus Infection,Coronavirus Infection, Hepatitis, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, and Others), Type of Drug Target (Virus Targets and Host Targets), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035’ market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the antiviral drugs market. The market research report also includes an in-depth analysis, highlighting the capabilities of antiviral drug developers engaged in antiviral drugs market.

This image represents the current market landscape of clinical-stage antiviral drugs. More than 40% of the antiviral drug candidates are currently in phase II clinical trials; polymerase inhibition and protease inhibition are the most popular mechanisms of action This image highlights partnerships activity in Antiviral Drugs domain. The growing interest is also evident from the rise in partnership activity; in fact, the maximum number of collaborations related to antiviral drugs were inked in the last two years This image provides information on investments that have been made into companies engaged in the antiviral drugs domain. Several investors, having realized the opportunity within this segment, have invested over USD 5.5 billion across various funding rounds in the past four years

Amongst other elements, the market report features:

  • A general overview of the antiviral drugs, along with information on types of viruses and viral diseases, different mechanism of action of antiviral drugs and characteristics and advantages offered by the antiviral drugs. The chapter concludes with a discussion on the challenges associated with the development of antiviral drugs and future prospects in antiviral drugs market.
  • A detailed assessment of the current market landscape of commercially available antiviral drugs, based on several relevant parameters, such as year of approval, type of dosage form (tablets, capsules, liquids, powders and others /unspecified), type of molecule (small molecules, biologics), type of target virus (DNA virus and RNA virus), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), dosing frequency, mechanism of action (polymerase inhibition, protease inhibition, reverse transcriptase inhibition, nonnucleoside reverse transcriptase inhibition, integrase strand transfer inhibition, nucleoside reverse transcriptase inhibition, NS5A inhibition, CYP3A inhibition, neuraminidase inhibition, glycoprotein inhibition, immunostimulation, interferon alpha stimulation and viral fusion protein inhibition) and target indication (human immunodeficiency virus infection, hepatitis C infection, hepatitis B infection, herpes simplex virus infection, influenza virus infection, cytomegalovirus infection, coronavirus infection, ebolavirus infection and other indications). In addition, it provides details on the antiviral drug developers, along with analyses based on their year of establishment, company size, geographical location and leading players (in terms of number of approved antiviral drugs). 
  • A detailed assessment of the current market landscape of clinical-stage antiviral drugs, based on several relevant parameters, such as phase of development (phase I, phase I/II, phase II, phase II/III and phase III), type of molecule (small molecules, biologics), type of dosage form (tablets, capsules, liquids, powders and others /unspecified), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), target indication (coronavirus infection, human immunodeficiency virus infection, hepatitis B infection, influenza virus infection, hepatitis C infection, respiratory syncytial virus infection, human papillomavirus infection, herpes simplex virus infection and other indications), type of developer (industry and industry / non-industry), type of therapy (monotherapy and combination therapy), target patient segment, mechanism of action (viral replication inhibition, anti-inflammation, immunostimulants, viral spike protein inhibition, interleukin receptor antagonists, polymerase inhibition, protease inhibition, viral entry inhibition, nucleoside reverse transcriptase inhibition, fusion protein inhibition, capsid protein inhibition, toll-like receptor antagonists, nonnucleoside reverse transcriptase inhibition, tyrosine kinase inhibition, viral core protein inhibition, Janus Kinases inhibition and HIV integrase inhibition), type of target virus (DNA virus and RNA virus) and number of doses. In addition, it provides details on the companies engaged in the development of clinical-stage antiviral drugs, based on their year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).
  • An analysis of partnerships that have been inked by stakeholders engaged in antiviral drugs market, since 2019, covering instances of clinical trial agreements, R&D agreements, product development and commercialization agreements, manufacturing agreements, product development agreements, commercialization agreements, acquisitions and mergers, product licensing agreements, supply agreements, manufacturing and commercialization agreements, product development and distribution agreements, technology licensing agreements, manufacturing and distribution agreements, distribution agreements and others. Further, the partnership activity in antiviral drugs market has been analyzed based on several relevant parameters, such as year of partnership, type of partnership, target indication, type of target virus, type of partner, most active players (in terms of number of partnerships) and regional distribution of collaborations. 
  • A detailed analysis of investments that have been made into companies engaged in the antiviral drugs domain, since 2019, capturing instances of venture capital financing, capital raised from IPOs and subsequent public offerings, grants, debts and other equity.  
  • A qualitative analysis of the five competitive forces, including threats for new entrants, bargaining power of drug developers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors under an insightful Porter’s Five Forces framework.
  • Elaborate profiles of prominent players engaged in development of antiviral drugs, featuring a brief overview of the company, details on its product portfolio and recent developments with an informed future outlook. 
This image provides an insightful Porter’s Five Forces framework. The COVID-19 pandemic led to surge in demand for effective antiviral drugs in the pharmaceutical industry; several stakeholders have entered to tap the opportunities within this domain This image provides a detailed market sizing of Antiviral drugs market. The antiviral drugs market is expected to grow at a CAGR of 6.3%; currently, the majority share of the market (44%) is captured by drugs targeting HIV infections This image provides market segmentation of Antiviral drug domain. The opportunity associated with the antiviral drugs market is likely to be well distributed across various types of drug targets, therapies, and key geographical regions

The key objective of antiviral drugs market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for antiviral drugs market during the forecast period. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as  mechanism of action (fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors and others), target indication (human immunodeficiency virus infection,coronavirus infection, hepatitis, herpes simplex virus infection, cytomegalovirus infection, influenza, and others), type of drug target (virus targets and host targets), type of therapy (monotherapy and combination therapy) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.

Frequently Asked Questions

Question 1: What is the projected market growth of the antiviral drugs market?

Answer: The antiviral drugs market is expected to grow at compounded annual growth rate (CAGR) of 6.3% during the forecast period 2022 - 2035.

Question 2: Who are the leading companies in antiviral drugs market?

Answer: Examples of key companies engaged in antiviral drugs market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Novartis, Pfizer, Roche and ViiV Healthcare.

Question 3: What are antiviral drugs?

Answer: Antiviral drugs are pharmaceutical compositions utilized for the treatment of viral infections. These drugs also reduce the risk of spreading of infection and shorten the length of the infection as well.

Question 4: What is the antiviral drugs market size?

Answer: The antiviral drugs market size is estimated to be worth $57 billion in 2022.

Question 5: Examples of key companies engaged in antiviral drugs market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Novartis, Pfizer, Roche and ViiV Healthcare.

Answer: North America is the hub for antiviral drugs developers, with nearly 75% of the companies based in the region.

Question 6: Which type of formulation is most preferred for antiviral drugs?

Answer: Presently, close to 90% of the approved antiviral drugs are available in tablet and liquid formulations.

Question 7: How much funding has been raised in antiviral drugs market?

Answer: Since 2019, funding received by antiviral drugs developers have surpassed USD 5.5 billion, with majority of amount being raised in the year 2020.

Question 8: How do antiviral drugs work?

Answer: Antiviral drugs work by acting at any of the several steps within the viral replication cycle.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com